Harnessing whole-blood miRNAs and Small RNAs for cancer diagnostics

Small RNAs harboring regulatory function reflect the biology of developing tumor and immune system reactions and are prime targets of high-throughput expression profiling in whole-blood liquid biopsies.

Analyzing whole blood eliminates error-prone plasma processing at point of care, yet a large amount of uninformative data plagues the exploratory and financial potential of whole-blood analysis.

This webcast will describe how Hummingbird Diagnostics has addressed this dilemma with a pipeline for ultra-deep detection and validation of small RNAs. The pipeline has recently been used to uncover more accurate biomarkers for immunotherapy response prediction in advanced non-small cell lung cancer (NSCLC) patients.

You will learn:

Why small RNAs in blood can serve as disease biomarkers
Challenges in discovery and usage of small RNAs as biomarkers
How miRNA expression in blood can be used for prediction of therapy outcomes

About the speaker

Rasti Horos, PhD, Chief Technology Officer

Hummingbird Diagnostics GmbH

Rasti Horos joined Hummingbird Diagnostics GmbH in Heidelberg as a Lab Head in 2020. Later he became Vice President of Technology and is currently serving as the Chief Technology Officer. Dr. Horos holds a PhD in molecular hematology from the Erasmus University Medical Center in Rotterdam, The Netherlands.